Jw. Christman et al., STRATEGIES FOR BLOCKING THE SYSTEMIC EFFECTS OF CYTOKINES IN THE SEPSIS SYNDROME, Critical care medicine, 23(5), 1995, pp. 955-963
Objectives: To review and evaluate animal and human data regarding str
ategies to intervene in the pathogenesis of the sepsis syndrome by spe
cifically blocking the action of single cytokines. Data Sources: The E
nglish language medical literature was reviewed, including reports of
human clinical trials, animal experiments, and in vitro studies elucid
ating cellular and molecular interactions. Study Selection: Emphasis w
as placed on controlled experimental studies that elucidated the effec
tiveness of antibodies, soluble receptors, and receptor antagonists in
intervening in the pathogenesis of the sepsis reaction. Data Extracti
on: This review focuses on data that directly involve the induction an
d regulation of protein mediators of sepsis, especially tumor necrosis
factor-alpha, interleukin-1 beta, interleukin-6, and interleukin-8. D
ata Synthesis: Information concerning the potential of cytokine blocke
rs in modulating the sepsis reaction is presented in a logical, clinic
ally oriented fashion. The purpose is to emphasize the potential role
of these agents by focusing on the actual existing data. Conclusions:
The pathophysiology of the sepsis reaction appears to involve the sequ
ential release of cytokines. Interventions designed to specifically bl
ock the biological effects of single cytokines appear to have a role i
n the management of sepsis syndrome, but well-designed, prospective, r
andomized, placebo-controlled clinical trials in well-defined clinical
population are necessary to define this role. These trials require th
e cooperation of clinical and basic scientists.